ASCO 2024 | KEYNOTE-A18: pembro or placebo with chemoradiotherapy in newly diagnosed high-risk cervical cancer

Domenica Lorusso, MD, PhD, from the Fondazione IRCCS National Cancer Institute of Milan, Milan, Italy, discusses the results of the Phase III ENGOT-cx11/GOG-3047/KEYNOTE-A18 trial (NCT04221945) evaluating the efficacy and safety of adding pembrolizumab to chemoradiotherapy in treating locally advanced cervical cancer. Conducted at 176 medical centers across 30 countries, this randomized, double-blind, placebo-controlled trial involved 1060 adults with newly diagnosed, high-risk, locally advanced cervical cancer. Participants received either pembrolizumab or placebo alongside chemoradiotherapy, followed by maintenance pembrolizumab or placebo. The primary endpoints were progression-free survival and overall survival. Results showed that the pembrolizumab–chemoradiotherapy group had a 24-month progression-free survival (PFS) rate of 68% compared to 57% in the placebo group, with a hazard ratio for disease progression or death of 0.70, meeting the primary objective. Overall survival (OS) at 24 months was 87% in the pembrolizumab group versus 81% in the placebo group, with grade 3 or higher adverse event rates of 75% and 69%, respectively. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.